Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Last Updated: November 28, 2021

DrugPatentWatch Database Preview

Patent: 10,335,486

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 10,335,486
Title:MRNA combination therapy for the treatment of cancer
Abstract: The present disclosure relates to the use of nucleic acid (e.g., mRNA) combination therapies for the treatment of cancer. The disclosure provides compositions, and methods for their preparation, manufacture, and therapeutic use, wherein those compositions comprise at least two polynucleotides (e.g., mRNAs) in combination wherein the at least two polynucleotides are selected from the group consisting of (i) a polynucleotide encoding an immune response primer (e.g., IL23), (ii) a polynucleotide encoding an immune response co-stimulatory signal (e.g., OX40L), (iii) a polynucleotide encoding a checkpoint inhibitor (e.g., an anti CTLA-4 antibody), and, (iv) a combination thereof. The therapeutic methods disclosed herein comprise, e.g., the administration of a combination therapy disclosed herein for the treatment of cancer, e.g., by reducing the size of a tumor or inhibiting the growth of a tumor, in a subject in need thereof. In some aspects, the combination therapies disclosed herein disclosed are administered intratumorally.
Inventor(s): Frederick; Joshua P. (Boston, MA), Hewitt; Susannah (Jamaica Plain, MA), Bai; Ailin (Newton, MA), Hoge; Stephen G. (Brookline, MA), Presnyak; Vladimir (Cambridge, MA), McFadyen; Iain (Arlington, MA), Benenato; Kerry (Sudbury, MA), Kumarasinghe; Ellalahewage Sathyajith (Harvard, MA)
Assignee: ModernaTX, Inc. (Cambridge, MA)
Application Number:15/996,146
Patent Claims:see list of patent claims

Details for Patent 10,335,486

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Bristol-myers Squibb Company YERVOY ipilimumab Injection 125377 2011-03-25 ⤷  Free Forever Trial 2036-05-18
Merck Sharp & Dohme Corp. KEYTRUDA pembrolizumab For Injection 125514 2014-09-04 ⤷  Free Forever Trial 2036-05-18
Merck Sharp & Dohme Corp. KEYTRUDA pembrolizumab Injection 125514 2015-01-15 ⤷  Free Forever Trial 2036-05-18
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.